Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stuart Johnson

Showing results (91-100 of 169) with videos related to

Pageof 17
Sort By:
Infection Control and Hospital Epidemiology|July 11, 2007
Onset of symptoms and time to diagnosis of Clostridium difficile-associated disease following discharge from an acute care hospitalHeidi T Chang, Dorota Krezolek, Stuart Johnson, et al.
Infection Control and Hospital Epidemiology|July 18, 2023
Characteristics and outcomes of <i>Clostridioides difficile</i> infection after a change in the diagnostic testing algorithmAndrew S Crone, Lorinda M Wright, Adam Cheknis, et al.
The American Journal of Gastroenterology|January 12, 2022
Why Do ACG and AGA Guidelines Differ for the Use of Probiotics and the Prevention of CDI?Lynne V McFarland, Ravina Kullar, Stuart Johnson, et al.
Microbiology Spectrum|March 28, 2023
Effective Colonization by Nontoxigenic Clostridioides difficile REA Strain M3 (NTCD-M3) Spores following Treatment with Either Fidaxomicin or VancomycinSusan P Sambol, Andrew M Skinner, Fidel Serna-Perez, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|March 14, 2021
A Tapered-pulsed Fidaxomicin Regimen Following Treatment in Patients With Multiple Clostridioides difficile Infection RecurrencesAndrew M Skinner, Xing Tan, Benjamin D Sirbu, et al.
Antimicrobial Agents and Chemotherapy|May 23, 2007
In vitro activities of 15 antimicrobial agents against 110 toxigenic clostridium difficile clinical isolates collected from 1983 to 2004David W Hecht, Minerva A Galang, Susan P Sambol, et al.
Anaerobe|July 17, 2018
Correlation between restriction endonuclease analysis and PCR ribotyping for the identification of Clostridioides (Clostridium) difficile clinical strainsLarry K Kociolek, Eric R Perdue, Warren N Fawley, et al.
Journal of Clinical Microbiology|May 8, 2003
Fatal case of endocarditis due to Weissella confusaJames D Flaherty, Paul N Levett, Floyd E Dewhirst, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|July 4, 2012
Relapse versus reinfection: recurrent Clostridium difficile infection following treatment with fidaxomicin or vancomycinIris Figueroa, Stuart Johnson, Susan P Sambol, et al.
Open Forum Infectious Diseases|January 23, 2023
Microbiota-Based Live Biotherapeutic RBX2660 for the Reduction of Recurrent <i>Clostridioides difficile</i> Infection in Older Adults With Underlying ComorbiditiesGlenn Tillotson, Laurie Archbald-Pannone, Stuart Johnson, et al.
Pageof 17

Showing results (91-100 of 169) with videos related to

Sort By:
Pageof 17
Infection Control and Hospital Epidemiology|July 11, 2007
Onset of symptoms and time to diagnosis of Clostridium difficile-associated disease following discharge from an acute care hospitalHeidi T Chang, Dorota Krezolek, Stuart Johnson, et al.
Infection Control and Hospital Epidemiology|July 18, 2023
Characteristics and outcomes of <i>Clostridioides difficile</i> infection after a change in the diagnostic testing algorithmAndrew S Crone, Lorinda M Wright, Adam Cheknis, et al.
The American Journal of Gastroenterology|January 12, 2022
Why Do ACG and AGA Guidelines Differ for the Use of Probiotics and the Prevention of CDI?Lynne V McFarland, Ravina Kullar, Stuart Johnson, et al.
Microbiology Spectrum|March 28, 2023
Effective Colonization by Nontoxigenic Clostridioides difficile REA Strain M3 (NTCD-M3) Spores following Treatment with Either Fidaxomicin or VancomycinSusan P Sambol, Andrew M Skinner, Fidel Serna-Perez, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|March 14, 2021
A Tapered-pulsed Fidaxomicin Regimen Following Treatment in Patients With Multiple Clostridioides difficile Infection RecurrencesAndrew M Skinner, Xing Tan, Benjamin D Sirbu, et al.
Antimicrobial Agents and Chemotherapy|May 23, 2007
In vitro activities of 15 antimicrobial agents against 110 toxigenic clostridium difficile clinical isolates collected from 1983 to 2004David W Hecht, Minerva A Galang, Susan P Sambol, et al.
Anaerobe|July 17, 2018
Correlation between restriction endonuclease analysis and PCR ribotyping for the identification of Clostridioides (Clostridium) difficile clinical strainsLarry K Kociolek, Eric R Perdue, Warren N Fawley, et al.
Journal of Clinical Microbiology|May 8, 2003
Fatal case of endocarditis due to Weissella confusaJames D Flaherty, Paul N Levett, Floyd E Dewhirst, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|July 4, 2012
Relapse versus reinfection: recurrent Clostridium difficile infection following treatment with fidaxomicin or vancomycinIris Figueroa, Stuart Johnson, Susan P Sambol, et al.
Open Forum Infectious Diseases|January 23, 2023
Microbiota-Based Live Biotherapeutic RBX2660 for the Reduction of Recurrent <i>Clostridioides difficile</i> Infection in Older Adults With Underlying ComorbiditiesGlenn Tillotson, Laurie Archbald-Pannone, Stuart Johnson, et al.
Pageof 17